Tedisamil: a new novel antiarrhythmic

Bibliography

• KANNEL WB, WOLF PA, BENJAMIN EJ et al: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. Cardiol (1998) 82:2N–9N.
   Google Scholar
• ANDERSON J: Acute treatment of atrial fibrillation and flutter. j. Am. Coll. Cardiol (1996) 17:17–21.
   Google Scholar
• COPLEN SE, ANTMAN EM, BERLIN JA et al.: Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion. A meta-analysis of randomised control trials. Circulation (1990) 82:1106–1116.
   Google Scholar
• •The classic paper suggesting that antiarrhythmic agents postcardioversion may be harmful and maintain sinus rhythm in only - 50% of the patients at 1 year.
   Google Scholar
• THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL INVESTIGATORS: Preliminary report: effect of ecainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. New Engl. I Med. (1989) 321:406–412.
   PubMed Web of Science ®Google Scholar
• RAWLES JM, METCALF MJ, JENNINGS K: Time of occurrence, duration and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br. Heart J. (1990) 63:225–227.
   PubMedGoogle Scholar
• MOSS AJ, DAVIS HT, CONARD DL et al.: Digitalis associated mortality after myocardial infarction. Circulation (1981); 64:1150–1156.
   PubMed Web of Science ®Google Scholar
• HILLEMAN DE, SPINLER A: Conversionof recent onset of atrial fibrillation with amiodarone: a meta-analysis of randomised control trials. Pharmacotherapy (2002) 22:66–74.
   PubMed Web of Science ®Google Scholar
• JUUL-MOLLER S, EDVARSSON N, REHGVIST-AHLBERG N et al.: Sotalol versus quinidine for maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation. Circulation (1990) 82:1932–1939.
   PubMed Web of Science ®Google Scholar
• LEE SH, CHEN SA, TAI DT: Comparisonof oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am. J. Cardiol (1997) 79:905–908.
   PubMed Web of Science ®Google Scholar
• REIMOLD SC, CANTILLON CO, FRIEDMAN PL et al.: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am. Cardiol (1993) 71:558–563.
   PubMed Web of Science ®Google Scholar
• SINGH SN, ZABL RG, YELLEN LG et al.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter. The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation (2000) 102:2385–2390.
   Google Scholar
• STAMBLER BS, WOOD MA, ELLENBOGEN KA: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation (1996) 94:1613–1621.
   PubMed Web of Science ®Google Scholar
• DUKES ID, MORAD M: Tedisamil inactivates transient outward K+ current in rat ventricular myocytes. Am. Physic] (1989) 257:H1746–H1749.
   PubMed Web of Science ®Google Scholar
• BERGER F, BORCHARD U, HAFNER D et al Different inhibition patterns of tedisamil for fast and slowly inactivation transient outward current in rat ventricular myocytes. Naunyn-schiedeberg's Arch. Pharmacol (1998) 357:291–298.
   PubMed Web of Science ®Google Scholar
• WETTWERE, HIMMEL HM, AMOS GJ et al Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br: J Pharmacol. (1998) 125:659–666.
   PubMed Web of Science ®Google Scholar
• DUKES ID, CLEEMANN L, MORAD M: Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. Pharmacol Exp. Thec (1990) 254:560–569.
   PubMed Web of Science ®Google Scholar
• WETTWER E, GERWER M, TAMKUN MM et al.: Native versus cloned Kv1.5 channel: effects of tedisamil on human cardiac delayed rectifier currents. ESC Barcelona (1999) (Abstract 329)
   Google Scholar
• FAIVRE JR, BRIL A: Tedisamil inhibition of ATP-sensitive K+ channels in adult rat ventricular cells. J. MM. Cell. Cardiol (1992) 24:S40.
   Google Scholar
• CHI L, PARK JL, FRIEDRICHS GS et al.: Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br. J. Pharmacol (1996) 117:1261–1269.
   PubMed Web of Science ®Google Scholar
• FAIVRE JF, ROUANET S, BRIL A: Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031 and BRL-32872 on protein kinase-activated chloride current in guinea pig ventricular myocytes. Cardiovasc. Pharmacol (1998) 31:551–557.
   PubMed Web of Science ®Google Scholar
• BEATCH GN, ABRAHAM S, MACLEOD BA et al Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K+ current blocker. Br. J. Pharmacol. (1991) 102:13–18.
   PubMed Web of Science ®Google Scholar
• •A nice paper on the electrophysiological properties of tedisamil.
   Google Scholar
• DORIAN P, NEWMAN D: Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements. Cardiovasc. Res. (1997) 33:485–494.
   PubMed Web of Science ®Google Scholar
• •See reference [21].
   Google Scholar
• NEMETH M, VARRO A, VIRAG L et al: Frequency-dependent cardiac electrophysiologic effects of tedisamil: comparison with quinidine and sotalol. Cardiovasc. Pharmacol Ther. (1997) 2:273–284.
   PubMedGoogle Scholar
• •See reference [21].
   Google Scholar
• NEMETH M, VIRAG L, HALA 0 et al: The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Cardiovasc. Res. (1996) 31:246–248.
   PubMed Web of Science ®Google Scholar
• BARGHEER K, BODE F, KLEIN HU et al.: Prolongation on monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur: Heart (1994) 15:1409–1414.
   PubMed Web of Science ®Google Scholar
• WALLACE AA, STUPIENSKI RF 3rd, BASKIN EP et al.: Cardiac electrophysiologic and antiarrhythmic actions of tedisamil.J Pharmacol Exp. Ther: (1995) 273:168–175.
   Google Scholar
• CHI L, PARK JL, FRIEDRICHS GS et al:Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br. Pharmacol (1996) 117:1261–1269.
   PubMed Web of Science ®Google Scholar
• DORIAN P, NEWMAN D: Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements. Cardiovasc. Res. (1997) 33:485–494.
   PubMed Web of Science ®Google Scholar
• GROHS JG, FISCHER G, RABERGER G:Cardiac and hemodynamic effects of the selective bradycardic agent KC 8857 during exercise-induced myocardial ischemia. Eur: .1. Pharmacol (1989) 161:53–60.
   Google Scholar
• DUCHOSAL F, OPIE H: KC8857, a new compound with combined bradycardic and positive inotropic effects. MM. Cell. Cardiol (1987) 19:(Suppl. III) (Abstract 19).
   Google Scholar
• FUCHS A, BUSCHMANN G, ZIEGLER D et al Tedisamil: cardiac electrophysiologic and functional effects in guinea pigs. Naunyn-schiedeberg's Arch. Pharmacol (1989) 340:R72.
   Google Scholar
• DOGGRELL SA, NAND V: Effects of tedisamil on cardiovascular tissues isolated from normo and hypertensive rats. .1. Cardiovasc. Pharmacol (2001) 6:261–272.
   Google Scholar
• TSUCHIHASHI K, CURTIS MJ: Influence of tedisamil on the initiation and maintenance of ventricular fibrillation: chemical defibrillation by Ito blockade? .1. Cardiovasc. Pharmacol (1991) 18:445–456.
   PubMed Web of Science ®Google Scholar
• FRIEDRICHS GS, ABREU JN, DRISCOLL EM et al.: Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation. Cardiovasc. Pharmacol (1998) 31:56–66.
   PubMed Web of Science ®Google Scholar
• FISCHBACH PS, JOHNSTON PV, FRIEDRICHS GS et al: Tedisamil in a chronic canine model of atrial flutter. Cardiovasc. Pharmacol (1999) 34:212–218.
   PubMed Web of Science ®Google Scholar
• FISCHBACH PS, BARRETT TD, GOYALR et al.: Conversion of atrial fibrillation by the experimental drug tedisamil in two canine models. I Cardiovasc. Electrophysiol (2001) 12:1138–1144.
   PubMed Web of Science ®Google Scholar
• MITROVIC V, OEHM E, THORMANN J et al: Comparison of the potassium channel blocker tedisamil and the beta-adrenoceptor blocker esmolol and the calcium channel antagonist gallopamil in patients with coronary artery disease. Clin. Cardiol (1998) 21:492–502.
   PubMed Web of Science ®Google Scholar
• DEMOLIS JL, MARTEL C, FUNCK-BRENTANO C et al.: Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br.Pharmacol.(1997) 44:403–409.
   Web of Science ®Google Scholar
• HAYES E, COURTICE ID, ABRAHAM S et al: Acute toxicity of tedisamil, a new potassium channel blocking drug. Pharmacol Toxicol (1993) 73:257–261.
   PubMedGoogle Scholar
• CHURCH J, McLARNON JG: Tedisamil blocks BK-type Ca-dependent K± channels and modulates action potentials in rat hippocampal neurons. Neurosci. Lett. (2002) 319:79–82.
   PubMed Web of Science ®Google Scholar
• KREYE VA, PFRUNDER D, THEISS U: Effects of the KE channel blocker tedisamil on 86Rb efflux induced by cromakalim, high potassium and noradrenaline and on mechanical tension in rabbit isolated vascular smooth muscle. Naunyn-schmiedeberg's Arch. Pharmacol(1992) 345:238–243.
   Google Scholar
• BRAY K, QUAST U: Differential inhibition by tedisamil (KC 8857) and glibenclamide of the responses to cromakalim and minoxidil sulphate in rat isolated aorta. Naunyn-schmiedeberg's Arch. Pharmacol (1992) 345:244–250.
   Google Scholar
• THORMANN J, MITROVIC V, RIEDEL H et al.: Tedisamil (KC 8857) is a new specific bradycardic drug: does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease. Am. Heart j (1993) 125:1233–1246.
   PubMed Web of Science ®Google Scholar
• HERMANN HP, OHLER A, JUST H et al Cardiac and hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestiveheart failure due to dilated cardiomyopathy. Cardiovasc. Pharmacol (1998) 32:969–972.
   PubMed Web of Science ®Google Scholar
• BARRETT TD, HENNAN JK, FISCHBACH PS et al: Tedisamil and dofetilide induced torsades de pointes, rate and potassium depenence. Br. .1. Pharmacol (2001) 132:1493–500.
   PubMed Web of Science ®Google Scholar
• MITROVIC V, OEHM E, THORMANN J et al: Potassium channel openers and blockers in coronary artery disease. Comparison to beta-blockers and calcium antagonists. Herz (2000) 25:130–142.
   Google Scholar
• FOX KM, HENDERSON JR, KASKI JC et al.: Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart (2000) 83:167–171.
   PubMed Web of Science ®Google Scholar
• •A nice paper on the anti-ischaemic properties of tedisamil.
   Google Scholar
• KOWEY PR, DORIAN P, BECKMANN K et al: Tedisamil for rapid conversion of recent onset atrial fibrillation and flutter to normal sinus rhythm. The North American Socieg, of Padng and Electrophysiology (NASPE), Washington, US (2003) (Abstract 417). Affiliation Bethan Freestone & Gregory YH Lipt lAuthor for corespondence Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK Tel: +44 0121 5075080; Fax: +44 0121 554 4083; E-mail: [email protected]
   Google Scholar